- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00386373
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
Use and Tolerability of Imatinib Mesylate (Gleevec®) in Patients With Philadelphia-Positive Chronic Myeloid or Acute Leukemia During the First 100 Days Following Bone Marrow or Stem Cell Transplantation
Primary Objective:
1. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+) CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell transplantation.
Secondary Objectives:
- To identify any clinically significant drug interactions with imatinib in the post-transplant setting.
- To develop specific monitoring parameters for imatinib use when utilized in the early post-BMT setting.
- To record one-year survival data in this patient cohort to assess any effect of early imatinib administration on this endpoint.
연구 개요
상세 설명
Imatinib mesylate is an FDA-approved, commercially available drug for patients with acute or chronic leukemias carrying the Philadelphia chromosome. Women who are able to have children must have a negative blood pregnancy test before taking this drug
No earlier than three weeks after the bone marrow or stem cell transplant, you will start taking imatinib mesylate by mouth. You will take it once or twice a day until roughly 100 days following the transplant or until you are released from the Houston area by your M. D. Anderson physician. Imatinib mesylate should be taken with a meal and a glass of water, preferably in the morning.
The dose will be gradually increased as long as you don't experience severe side effects. If severe side effects occur, imatinib will be stopped, either temporarily or permanently.
After about 100 days (or after leaving Houston) the medication may be continued at the discretion of the study doctor, but the study will be considered completed.
This is an investigational study. A total of up to 40 patients will take part in this study. All will be enrolled at M. D. Anderson. The study is partially funded by the manufacturer of imatinib mesylate (see below), although the drug is not provided free of charge.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- U.T.M.D. Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients with Ph(+) CML and/or CML with bcr-abl rearrangement and diploid cytogenetics not eligible for protocols of higher priority (e.g. ID02-901, DM99-081, DM97-206, etc).
- The disease must be beyond first chronic phase according to IBMTR criteria (i.e. accelerated phase, blastic phase, second chronic phase) at the time of transplant.
- Patients with Ph(+) acute lymphocytic (or myeloid) leukemia.
- Patients with diploid cytogenetics but molecular evidence of bcr-abl rearrangement are also eligible.
- Age >/= 16 years
- Unsupported ANC at least 1500 and unsupported platelet count of at least 50K following BMT.
- Patients may have received prior chemotherapy for their disease or be previously untreated.
- Patients must have received an allogeneic bone marrow or stem cell transplant. Allogeneic transplant types may include matched sibling donors, mismatched related donors, or unrelated donors. All preparative regimens acceptable.
- Signed informed consent
- Zubrod status </= 3
- Adequate hepatic (bilirubin </= 3 mg/dl, transaminases < 4 x upper limit of normal) and renal function (serum creatinine </= 3 mg/dl )
Exclusion Criteria:
- Grade III/IV cardiac problems as defined by the NYHAC
- History of hypersensitivity to imatinib
- Pregnant and lactating women
- HIV positive
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: 이마티닙 메실레이트
|
Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Toxicity Rate
기간: 100 Days and 1 Year
|
100 Days and 1 Year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Paolo Anderlini, MD, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2003-0433
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Imatinib Mesylate에 대한 임상 시험
-
Institut BergoniéNovartis종료됨
-
Centre Oscar Lambret완전한
-
Baylor College of Medicine모병만성 골수성 백혈병 | 만성 골수성 백혈병, BCR/ABL 양성, 관해 상태 | 차도의 만성 골수성 백혈병미국
-
Dong-A ST Co., Ltd.완전한만성 골수성 백혈병 | 위장관 간질 종양대한민국
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.완전한
-
Medical University of South CarolinaColumbia University완전한
-
Dr. Jurjan AmanExvastat Ltd.; Simbec-Orion Group; KABS laboratories종료됨코로나19 | 내피 기능 장애 | 급성 호흡기 장애 증후군 | 급성호흡곤란증후군 | 폐부종네덜란드
-
Peking University Third HospitalBeijing Hospital완전한